The nation of Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' demand for confidential data.
This move was revealed following a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative has since stated that the US was requesting biological samples for scientific study and commercial gain but refused to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further negotiations to find a agreement agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
This development comes after a similar case in neighbouring Kenya, where a court halted a similar deal with the US after concerns were filed about the safety of citizens' medical information.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on statements, Sixteen African countries have to date signed similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, without any equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our country would provide the raw materials for medical research with no assurance that the end products would be accessible to our population should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This mechanism is intended to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that negotiations should continue since a large portion of the nation's HIV programmes depended on international support.
"Where technical issues arise, including those involving data governance or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
The situation highlights the complex debate between receiving vital international aid and protecting national sovereignty in an ever more data-driven world.